Masimo (NASDAQ:MASI) had its price objective upped by Raymond James from $235.00 to $250.00 in a research report report published on Wednesday morning, BenzingaRatingsTable reports. They currently have an outperform rating on the medical equipment provider’s stock.
A number of other research firms have also recently commented on MASI. UBS Group boosted their target price on shares of Masimo from $207.00 to $245.00 and gave the stock a buy rating in a research note on Thursday, April 30th. BTIG Research restated a hold rating on shares of Masimo in a research report on Thursday, July 9th. Needham & Company LLC lowered shares of Masimo from a buy rating to a hold rating in a research report on Monday, April 20th. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a research report on Wednesday, July 8th. Finally, Stifel Nicolaus boosted their price target on shares of Masimo from $200.00 to $245.00 and gave the stock a buy rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $216.14.
MASI stock opened at $220.12 on Wednesday. The stock has a market capitalization of $12.10 billion, a P/E ratio of 57.03, a P/E/G ratio of 4.11 and a beta of 0.92. The firm has a 50-day simple moving average of $228.29 and a 200-day simple moving average of $202.59. Masimo has a 52 week low of $139.36 and a 52 week high of $258.00.
In related news, Director Adam Mikkelson sold 1,498 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $216.01, for a total transaction of $323,582.98. Following the sale, the director now directly owns 2,802 shares of the company’s stock, valued at approximately $605,260.02. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director H Michael Cohen sold 587 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $225.37, for a total transaction of $132,292.19. Following the sale, the director now directly owns 717 shares in the company, valued at $161,590.29. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,335 shares of company stock worth $749,625. Company insiders own 11.50% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. C M Bidwell & Associates Ltd. purchased a new stake in shares of Masimo in the 1st quarter valued at approximately $25,000. Parallel Advisors LLC increased its position in shares of Masimo by 272.1% in the 2nd quarter. Parallel Advisors LLC now owns 160 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 117 shares during the last quarter. Credit Agricole S A purchased a new stake in shares of Masimo in the 1st quarter valued at approximately $29,000. Altshuler Shaham Ltd increased its position in shares of Masimo by 91.0% in the 1st quarter. Altshuler Shaham Ltd now owns 170 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 81 shares during the last quarter. Finally, GQ Asset Management LLC purchased a new stake in shares of Masimo in the 1st quarter valued at approximately $32,000. 84.39% of the stock is currently owned by hedge funds and other institutional investors.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.